Direct medical costs for patients with schizophrenia: a 4-year cohort study from health insurance claims data in Guangzhou city, Southern China

[1] Kovacs G(2018)Direct healthcare cost of schizophrenia—European overview Eur Psychiatry 48 79-92

[2] Almasi T(2015)Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 386 743-800

[3] Millier A(2008)Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues Int J Methods Psychiatr Res 17 55-61

[4] Toumi M(2009)Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey Lancet 373 2041-2053

[5] Horvath M(2004)The global costs of schizophrenia Schizophr Bull 30 279-293

[6] Koczian K(2008)Outpatient antipsychotic treatment and inpatient costs of schizophrenia Schizophr Bull 34 173-180

[7] Gotze A(2013)The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy Clinicoecon Outcomes Res 5 407-418

[8] Kalo Z(2015)Consolidating the social health insurance schemes in China: towards an equitable and efficient health system Lancet 386 1484-1492

[9] Zemplenyi AT(2011)Medical aid policy for psychiatric patients in Changzhou city, China Med J Chin People Health 23 2983-2984

[10] Vos T(2016)The economic burden of schizophrenia in the United States in 2013 J Clin Psychiatry 77 764-771

[1] Kovacs G(2018)Direct healthcare cost of schizophrenia—European overview Eur Psychiatry 48 79-92

[2] Almasi T(2015)Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 386 743-800

[3] Millier A(2008)Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues Int J Methods Psychiatr Res 17 55-61

[4] Toumi M(2009)Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey Lancet 373 2041-2053

[5] Horvath M(2004)The global costs of schizophrenia Schizophr Bull 30 279-293

[6] Koczian K(2008)Outpatient antipsychotic treatment and inpatient costs of schizophrenia Schizophr Bull 34 173-180

[7] Gotze A(2013)The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy Clinicoecon Outcomes Res 5 407-418

[8] Kalo Z(2015)Consolidating the social health insurance schemes in China: towards an equitable and efficient health system Lancet 386 1484-1492

[9] Zemplenyi AT(2011)Medical aid policy for psychiatric patients in Changzhou city, China Med J Chin People Health 23 2983-2984

[10] Vos T(2016)The economic burden of schizophrenia in the United States in 2013 J Clin Psychiatry 77 764-771